Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: Results of the IDASPHERE phase i trial

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 11, 2014, Pages 1301-1313

  Boulin, M ^a,b   Hillon, P ^a,b   Cercueil, J P ^a,b   Bonnetain, F ^c   Dabakuyo, S ^d   Minello, A ^a,b   Jouve, J L ^a,b   Lepage, C ^a,b   Bardou, M ^b,e   Wendremaire, M ^b   Guerard, P ^b   Denys, A ^f   Grandvuillemin, A ^b   Chauffert, B ^g   Bedenne, L ^a,b   Guiu, B ^a,b  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF BESANÇON   (France)

^d Georges Francois Leclerc Anticancer Centre   (France)

^e INSERM   (France)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DRUG CARRIER; DRUG ELUTING BEAD; GAMMA GLUTAMYLTRANSFERASE; IDARUBICIN; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; AGED; ALLERGIC REACTION; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLEEDING; CANCER GROWTH; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOSE LIMITING TOXICITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RELEASE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMATOMA; HUMAN; HYPERBILIRUBINEMIA; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOXIA; INFECTION; LEUKOPENIA; LIVER CELL CARCINOMA; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOCYTOPENIA; TOXICOLOGICAL PARAMETERS; UNSPECIFIED SIDE EFFECT; VOMITING;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IDARUBICIN; LIVER NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84900021416     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12746     Document Type: Article

References (37)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Forner A, Llovet JM, Bruix J,. Hepatocellular carcinoma. Lancet 2012; 379: 1245-55.
3. Lo CM, Ngan H, Tso WK, et al,. Randomised controlled trial of transarterial lipiodol chemoembolisation for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-71.
4. Llovet JM, Real MI, Montana X, et al,. Arterial embolization or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-9.
5. Camma C, Schepis F, Orlando A, et al,. Transarterial chemoembolisation for unresectable hepatocellular carcinoma: meta-analysis of randomised controlled trials. Radiology 2002; 224: 47-54.
6. Llovet JM, Bruix J,. Systematic review of randomised trials for unresectable hepatocellular carcinoma: chemoembolisation improves survival. Hepatology 2003; 37: 429-42.
7. Marelli L, Stigliano R, Triantos C, et al,. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomised studies. Cardiovasc Intervent Radiol 2007; 30: 6-25.
8. Boulin M, Guiu S, Chauffert B, et al,. Screening of anticancer drugs for chemoembolisation of hepatocellular carcinoma. Anticancer Drugs 2011; 22: 741-8.
9. Broggini M, Italia C, Colombo T, Marmonti L, Donelli MG,. Activity and distribution of i.v. and oral 4-demethoxydaunorubicin in murine experimental tumours. Cancer Treat Rep 1984; 68: 739-47.
10. Roovers DJ, Van Vliet M, Bloem AC, Lokhorst HM,. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines. Leuk Res 1999; 23: 539-48.
11. Mankhetkorn S, Dubru F, Hesschenbrouck J, Fiallo M, Garnier-Suillerot A,. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. Mol Pharm 1996; 49: 532-9.
12. Berman E, McBride M,. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 1992; 79: 3267-73.
13. Minemura M, Tanimura H, Tabor E,. Overexpression of multidrug resistance genes MDR1 and Cmoat in human hepatocellular carcinoma and hepatoblastoma cell lines. Int J Oncol 1999; 15: 559-63.
14. Vander Borght S, Komuta M, Libbrecht L, et al,. Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int 2008; 28: 1370-80.
15. Lewis AL, Taylor RR, Hall B, Gonzalez MV, Willis SL, Stratford PW,. Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolisation. J Vasc Interv Radiol 2006; 17: 335-42.
16. Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF,. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 2006; 12: 2563-7.
17. Varela M, Real MI, Burrel M, et al,. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474-81.
18. Poon RT, Tso WK, Pang RWC, et al,. A phase I/II trial of chemoembolisation for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 2007; 5: 1100-8.
19. Bruix J, Sherman M, Llovet JM, et al,. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the liver. J Hepatol 2001; 35: 421-30.
20. O'Quigley J, Pepe M, Fisher L,. Continual Reassessment Method: a practical design for phase I clinical studies in cancer. Biometrics 1990; 46: 33-48.
21. O'Quigley J, Shen LZ,. Continual reassessment method: a likelihood approach. Biometrics 1996; 52: 673-84.
22. Common Terminology Criteria for Adverse Events v3.0 (2006). Available at: http://www.ctep.cancer.gov/forms/CTCAEv3.pdf. Accessed September 16, 2013.
23. Lencioni R, Llovet JM,. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
24. Aaronson NK, Ahmedzai S, Bergman B, et al,. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
25. Osoba D,. Interpreting the meaningfulness of changes in health-related quality of life scores: lessons from studies in adults. Int J Cancer 1999; 12 (Suppl.): S132-7.
26. Grosso M, Vignali C, Quaretti P, et al,. Transarterial chemoembolisation for hepatocellular carcinoma with drug eluting microspheres: preliminary results from an Italian multicentre study. Cardiovasc Intervent Radiol 2008; 31: 1141-9.
27. Lammer J, Malagari K, Vogl T, et al,. Prospective randomised study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52.
28. Liu DM, Kos S, Buczkowski A, et al,. Optimization of doxorubicin loading for superabsorbent polymer microspheres: in vitro analysis. Cardiovasc Intervent Radiol 2012; 35: 391-8.
29. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF,. Phase II trial of sorafenib combined with concurrent transarterial chemoembolisation with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 2011; 29: 3960-7.
30. Olweny CL, Toya T, Katongole-Mbidde E, Mugerwa J, Kyalwazi SK, Cohen H,. Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication. Cancer 1975; 36: 1250-7.
31. Burroughs A, Hochhauser D, Meyer T,. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol 2004; 5: 409-18.
32. Watanabe S, Nishioka M, Ohta Y, Ogawa N, Ito S, Yamamoto Y,. Prospective and randomised controlled study of chemoembolisation therapy in patients with advanced hepatocellular carcinoma. Cooperative Study Group for Liver Cancer Treatment in Shikoku area. Cancer Chemother Pharmacol 1994; 33 (Suppl. 1): S93-6.
33. Kawai S, Tani M, Okamura J, et al,. Prospective and randomised trial of lipiodol-transcatheter arterial chemoembolisation for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Semin Oncol 1997; 24 (Suppl. 6): S38-45.
34. Favelier S, Boulin M, Hamza S, et al,. Lipiodol trans-arterial chemoembolisation of hepatocellular carcinoma with idarubicin: first experience. Cardiovasc Intervent Radiol 2013; 36: 1039-46.
35. Robert J,. Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet 1993; 24: 275-88.
36. Bauer KS, Karp JE, Garimella TS, Wu S, Tan M, Ross DD,. A phase I pharmacological study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. Leuk Res 2005; 29: 263-71.
37. Prajapati HJ, Spivey JR, Hanish SI, et al,. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin-eluting beads transarterial chemoembolisation (DEB TACE). Ann Oncol 2013; 24: 965-73.